GLP1R and depressive symptom measurement: 2013). Our review also identified cases where semaglutide use coincided with the onset of MDD in two patients—one of whom had a prior history of depression, making it difficult to fully attribute causality to the medication. However, an analysis by McIntyre et al. (2013), using data from the FDA adverse event reporting system (FAERS), found no disproportionate reporting of suicidal behaviors, suicide attempts, or completed suicides for any FDA‐approved GLP‐1 RAs.